Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Frequent aspirin use associated with ovarian cancer risk-reduction
  • News

Frequent aspirin use associated with ovarian cancer risk-reduction

  • 7 September 2022
  • Janet Fricker
Frequent aspirin use associated with ovarian cancer risk-reduction
Total
0
Shares
0
0
0
0
0

Frequent aspirin (acetyl salicyclic acid) use is associated with lower ovarian cancer risk regardless of the presence of most ovarian cancer risk factors. The meta-analysis of data from two ovarian cancer consortia, published in Journal of Clinical Oncology, 22 July, found risk reductions were also observed among women with multiple ovarian cancer risk factors.

“This study, the largest to-date on aspirin use and ovarian cancer, provides evidence that frequent aspirin use is associated with lower ovarian cancer risk regardless of the presence of most other ovarian cancer risk factors,” write the authors. The study, they add, represents the first to examine effect modification by a comprehensive set of ovarian cancer risk factors.

Ovarian cancer is the fifth leading cancer killer of women, largely due to nonspecific symptoms and lack of early detection strategies. Inflammation-related exposures, such as endometriosis and pelvic inflammatory disease and circulating biomarkers of inflammation, have all been associated with ovarian cancer risk. Such findings raise the possibility that anti-inflammatory medications, such as aspirin, may lower the risk of ovarian cancer development. Pooled secondary analyses of randomised controlled trials of aspirin for cardiovascular disease (CVD) prevention have noted a decreased risk of female reproductive cancers with at least three years of aspirin use, although too few ovarian cancer cases were diagnosed to draw inferences for ovarian cancer.

In the current study, Lauren Hurwitz, from the US National Cancer Institute, and colleagues leveraged data from 17 studies (nine cohort studies from the Ovarian Cancer Cohort consortium, n=2,600; and eight case-control studies from the Ovarian Cancer Association Consortium n=5,726). The aim was to examine the association between frequent aspirin use and ovarian cancer risk, both overall and across subgroups of women with different ovarian cancer risk factors (endometriosis, obesity, family history of breast/ ovarian cancer, parity, oral contraceptive use and tubal ligation). For the studies, frequent aspirin use was defined as taking aspirin six or seven days per week, with no dose specified.

Results show that frequent aspirin use was associated with a 10% reduction in ovarian cancer risk in the cohort studies (HR 0.90; 95% CI 0.81-1.01) and a 16% reduced risk in the case-controlled studies (OR 0.84; 95% CI 0.72-0.98). A meta-analysis of both cohort and case-controlled studies found that, overall, frequent aspirin use was associated with a 13% reduction in ovarian cancer risk (RR 0.87; 95% CI 0.80-0.94).

Risk reductions with frequent aspirin use were similar across all ovarian cancer histotypes, but ‘particularly robust’ for patients with high-grade serous ovarian cancer (RR 0.86).

Consistent reductions were observed across most subgroups: for those with obesity (RR 0.79; 95% CI 0.67- 0.93), family history (RR 0.88; 95% CI 0.72-1.06), nulliparity (RR 0.83; 95% CI 0.64-1.09), oral contraceptive use ≥ five years (RR 0.91; 95% CI 0.77 to 1.08), and  tubal ligation (RR 0.93; 95% CI 0.77-1.08). However, frequent aspirin use was not associated with a lower risk of ovarian cancer among women with endometriosis (RR 1.15; 95% CI 0.80-1.65).

Furthermore, risk reduction increased with number of risk factors, for women with ≥ 2 risk factors (RR 0.81; 95% CI, 0.73-0.90).

“The consistency of the frequent aspirin use ovarian cancer association across the individual case-control and cohort study populations was notable and provides strong support for a beneficial effect of frequent aspirin use on ovarian cancer risk,” conclude the authors.

Regarding endometriosis, they suggest the inverse association was likely driven by “the small number of women with endometriosis and the limited power to detect associations within this subgroup”.

To maximize the population-level benefit/ risk ratio, the authors believe that use of aspirin for ovarian cancer chemo prevention may best be targeted to women at higher risk with two or more ovarian cancer risk factors.

“Since aspirin helped people who had two or more risk factors, we hope patients and clinicians can use this research to have an informed conversation when it comes to potential preventive measures. Individuals should consult their health care providers before beginning new medications in order to most appropriately balance any potential risks with the potential benefits,” says Britton Trabert, one of the investigators (Huntsman Cancer Institute, at The University of Utah).

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • Anti-inflammatories
  • aspirin
  • endometriosis
  • high grade serous ovarian cancer
  • inflammation
  • ovarian cancer risk
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Obituaries

Peter Boyle: a high-impact epidemiologist with contagious dreams

  • 5 August 2022
  • Anna Wagstaff
View Post
Next Article
  • News

UK consensus group calls for biomarker testing at point of diagnosis

  • 8 September 2022
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • News

Call-to-arms for Europe to provide essential paediatric anti-cancer medicines

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Exercise-stimulated myokine production can extend survival in advanced prostate cancer

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Five San Antonio take-aways to improve care of breast cancer patients

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Repurposed drug combination reduces risk of recurrence following surgery for colorectal cancer

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Aerobic activity to outcompete metastasis 

  • Janet Fricker
  • 2 December 2022
View Post
  • News

Ending cancer inequalities: European summit showcases new tools to inform policy

  • Anna Wagstaff
  • 30 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • Hansjörg Senn of St Gallen: A practice-changing career
    • 3 February 2023
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.